Hospira Issues a Voluntary Nationwide Recall For One Lot Of 0.25% Bupivacaine Hydrochloride Injection, USP Due to The Presence Of Particulate Matter Within a Single Vial

You are subscribed to Recalls, Market Withdrawals and Safety Alerts for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

 

 

Hospira Issues a Voluntary Nationwide Recall For One Lot Of 0.25% Bupivacaine Hydrochloride Injection, USP Due to The Presence Of Particulate Matter Within a Single Vial

08/05/2016 11:37 AM EDT

Lake Forest, IL - Hospira, Inc., a Pfizer company, is voluntarily recalling one lot of 0.25% Bupivacaine Hydrochloride Injection, USP (NDC: 0409-1159-02, Lot 59-064- DK, Expiry 1NOV2017) at the hospital/retail level due to the presence of particulate matter within a single vial. The issue was identified through a confirmed complaint.

For detailed information pertaining to this Recalls, Market Withdrawals and Safety Alerts message, please click the link at the beginning of this bulletin.

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? Please visit subscriberhelp.govdelivery.com
• Other inquiries? webmail@oc.fda.gov

---

This email was sent to filter@clubhouseb.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 1-888-INFO-FDA (1-888-463-6332)